BWI: GlaxoSmithKline Pharmaceuticals Announces Q2 Results

Source : GlaxoSmithKline Pharmaceuticals Limited Tuesday, August 12, 2014 2:36PM IST (9:06AM GMT)   (BSE:500660) GlaxoSmithKline Pharmaceuticals Announces Q2 Results   Mumbai, Maharashtra, India The core Pharmaceuticals business grew by 3.7 % for the quarter. The quarter continued to see the impact of the base effect of differential pricing cuts due to the Price Control Order, extending coverage to the National List of Essential Medicines (NLEM).   Commenting on the performance, Dr. Hasit B. Joshipura, Managing Director, said, “Growth has improved progressively across business verticals. During the quarter we continued to expand our Oncology portfolio with the launch of Vectibix™, which is the first Fully Human Monoclonal Antibody for the treatment of metastatic Colorectal Cancer (mCRC). “   About GlaxoSmithKline: GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com. To view the financial results click on: Statement of Standalone Unaudited Results for the Quarter and Six Months Ended 30th June, 2014   Media Contact Details Nandini Goswami, General Manager, Corporate Communications GlaxoSmithKline Pharmaceuticals Limited, ,+91 (22) 24959203 , nandini.x.goswami@gsk.com   KEYWORDS: Business/ Finance:Banking & Financial services, Business Services, Financial Analyst & Investors, Healthcare & biotechnology, Pharmaceutical, Stock Exchanges   If you wish to change your Business Wire India selection please visit on Business Wire India and use your personal username and password to login.   Submit your press release at http://www.businesswireindia.com

Note : This is system generated mail. Please do not reply to it.